Ontology highlight
ABSTRACT:
SUBMITTER: Hijiya N
PROVIDER: S-EPMC6923664 | biostudies-literature | 2019 Dec
REPOSITORIES: biostudies-literature
Hijiya Nobuko N Maschan Alexey A Rizzari Carmelo C Shimada Hiroyuki H Dufour Carlo C Goto Hiroaki H Kang Hyoung Jin HJ Guinipero Terri T Karakas Zeynep Z Bautista Francisco F Ducassou Stéphane S Yoo Keon Hee KH Zwaan Christian Michel CM Millot Frédéric F Aimone Paola P Allepuz Alex A Quenet Sara S Hourcade-Potelleret Florence F Hertle Sabine S Sosothikul Darintr D
Blood 20191201 23
Chronic myeloid leukemia (CML) is rare in children and accounts for ≤15% of all myeloid leukemia cases. When we initiated this study with nilotinib, imatinib was the only tyrosine kinase inhibitor indicated for pediatric patients with Philadelphia chromosome-positive (Ph+) CML in chronic phase (CP); alternative treatment options were needed, particularly for patients who developed resistance or intolerance (R/I) to imatinib. This phase 2 study enrolled pediatric patients with either Ph+ CML-CP R ...[more]